Clinical trial · Interventional
Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma: an Open Label, Single Arm, Phase II Study
NCT04329130CI-TRIAL-00044799unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this open label,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of Chidamide combination with lenalidomide for relapsed or refractory peripheral T-cell lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relapsed or Refractory Peripheral T-cell Lymphoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chidamide, Lenalidomide | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Chidamide combined Lenalidomide
- description
- Chidamide, 20 mg, twice per week; lenalidomide, 25 mg, d1-21, and rest for 7 days. one treatment cycle per 28 days.For patients with limited lesions and good drug response, local radiotherapy may be assessed by the investigator.
- interventionNames
- Drug: Chidamide, Lenalidomide
Primary outcomes (1)
- measure
- ORR
- timeFrame
- 4-years
- description
- Overall Response Rate
Secondary outcomes (3)
- measure
- PFS
- timeFrame
- 4-years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * peripheral T cell lymphoma (PTCL); * no remission or relapse after at least one previous systemic treatment； * at least one assessable lesion； * 18-75 years; * ECOG PS 0-2; * proper functioning of the major organs; * expected survival time ≥3 months. Exclusion Criteria: * previous received treatment of HDAC inhibitor or lenalidomide; * central nervous system (CNS) involvement; * serious heart problems; * known allergies to experimental drug ingredients; * diagnosed with or receiving treatment for a malignancy other than lymphoma; * uncontrolled active infection, with the exception of tumor-related b-symptom fever; * unable or unwilling to receive antithrombotic therapy; * history of deep vein thrombosis (DVT) or pulmonary embolism (PE) in the past 12 months;
References
Publications (0)
Data not yet available
No reference posted for this study.